For laboratory research use only. Not for human consumption. All compounds referenced in this article are sold by Explicit SARMs solely as reference materials for in-vitro and animal research by qualified professionals. Nothing here is medical advice, and no statement has been evaluated by the FDA. These materials are not intended to diagnose, treat, cure or prevent any disease.
TB-500 and BPC-157 are often sold together and sometimes in the same vial, which makes it easy to forget that they are unrelated molecules. This comparison sets out how they differ and why the differences matter for study design.
At a Glance
| BPC-157 | TB-500 | |
|---|---|---|
| What it is | Synthetic 15-amino-acid peptide, a partial fragment of a gastric “body protection compound” | Synthetic peptide based on the actin-binding region of thymosin beta-4 |
| Parent molecule | Gastric protein fragment | Thymosin beta-4 (43 amino acids) |
| Proposed mechanisms discussed | Angiogenesis, nitric oxide signaling, growth-factor pathways | Actin sequestration, cell migration |
| Evidence base | Mostly rodent and cell studies, concentrated in one research group | Mostly research on full-length thymosin beta-4 |
| WADA status | S0, non-approved substances | S2, peptide hormones, growth factors and related substances |
| Regulatory approval | None | None |
Different Origins
BPC-157 is a synthetic 15-amino-acid peptide whose sequence is a partial fragment of a protein originally isolated from gastric juice, often called “body protection compound.” TB-500 is a synthetic peptide based on the actin-binding region of thymosin beta-4, a naturally occurring 43-amino-acid protein that regulates actin, the main structural protein of the cell cytoskeleton. The two share no sequence and no parent molecule.
Different Evidence Problems
Each peptide has its own caveat. For BPC-157, the main question is independent replication, because so much of the literature comes from one group. For TB-500, the issue is attribution. Many claims cite studies of full-length thymosin beta-4, and those findings can’t be assumed to apply to the fragment. Our BPC-157 research overview and TB-500 research summary go further into each.
What This Means for Study Design
Because the proposed mechanisms differ, studies that look at the pair need separate arms for each peptide before a combined arm can be interpreted. Explicit SARMs supplies BPC-157 5mg, TB-500 5mg and the 1:1 BPC-157 / TB-500 Blend 10mg strictly as laboratory reference material. A certificate of analysis is available on request through our contact page, and our products are purity-tested by an independent third-party lab. Our guide to reading a COA explains what each section of the report should contain.
Frequently Asked Questions
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a synthetic fragment based on part of thymosin beta-4. Thymosin beta-4 is the full-length protein.
Are either of these approved for human use?
No. Both are sold strictly for laboratory research, and we do not provide dosing, administration or usage guidance.